Basel, March 27, 2023 — Novartis today announced positive topline results from an interim analysis of NATALEE, a Phase III trial evaluating Kisqali® (ribociclib) plus endocrine therapy (ET) in a broad ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results